Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 12:48 pm IST
Share
Ildong Holdings Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 3,649.95 million compared to KRW 1,585.6 million a year ago. Net loss was KRW 6,369.58 million compared to KRW 5,235.24 million a year ago. Basic loss per share from continuing operations was KRW 564 compared to KRW 464 a year ago. Basic loss per share was KRW 564 compared to KRW 471 a year ago.
For the nine months, sales was KRW 7,631.27 million compared to KRW 5,842.82 million a year ago. Net loss was KRW 20,667.54 million compared to KRW 6,776.16 million a year ago. Basic loss per share from continuing operations was KRW 1,830 compared to KRW 600 a year ago. Basic loss per share was KRW 1,830 compared to KRW 258 a year ago.
Ildong Holdings Co., Ltd., formerly Ildong Pharmaceuticals Co., Ltd., is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. It also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.
ILDONG HOLDINGS CO., LTD. 
